Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Diabetes Treatment
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 240085
For the Manufacturing, the Licensee, its Affiliates and permitted sublicensees shall have the exclusive license to manufacture Compounds and Products.
For the Transfer of Screening Technology, Licensor grants a nonexclusive, perpetual, irrevocable, worldwide license, including the right to grant sublicenses, under all of its intellectual property rights related to the FBPase screening technology to enable Licensee to exercise its rights, including, without
limitation, the development of Candidate Compounds, Recommended Compounds and Research
Compound shall mean a Research Compound, Recommended Compound, Candidate Compound or Licensed Compound.
Licensed Compound shall mean a Candidate Compound which Licensee has deemed a Licensed Compound.
Products shall mean pharmaceutical compositions incorporating a Licensed Compound. All formulations of the same drug substance for the same route of administration, such as oral, parenteral or intravenous, shall constitute a single Product.
IPSCIO Record ID: 239035
for discovery and commercialization of next generation compounds in the Field.
For the grant of option, Licensor grants to the Japanese Licensee an exclusive option to obtain an exclusive license to any one New Back-up Compound discovered by Licensor during the Discovery Period, and, of the Restated Agreement and otherwise on the terms and conditions set forth in the Restated Agreement.
For grant of negotiation right with Licensor during the Option Term for a new collaborative research, development and commercialization agreement between the parties for the discovery, development and commercialization of Next Generation Compounds in the Field.
CS-917 means that certain Compound known as CS-917 (also known as MB6322), which is a Licensed Compound under the Restated Agreement.
CS-917, a compound for the treatment of type 2 diabetes, is a prodrug of an orally active, potent and selective inhibitor of fructose-1, 6-bisphosphatase (FBPase), a regulatory enzyme in the pathway responsible for the production of glucose in the liver, known as the gluconeogenesis pathway.
IPSCIO Record ID: 202851
IPSCIO Record ID: 215177
Licensor grants an exclusive license in the Territory, with the right to sublicense, under the Licensor Rights existing as of the Effective Date, solely to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Field in the Territory as contemplated by this Agreement and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.
Licensor grants a non-exclusive, worldwide license, including the right to sublicense in conjunction with a sublicense permitted by this agreement, to use the Licensors Marks on Product packaging, labeling, advertising and Promotional Material.
For IT improvements, Licensor grants a worldwide, nonexclusive license in the Territory to practice under the rights of Licensor to any such Licensor Rights and Improvements to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Territory as contemplated by this Agreement and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.
Each Party grants the other Party an exclusive option to enter into an agreement for the Development of Option Compound(s) Controlled by the granting Party.
The Compound means exendin-4, an amino acid sequence.
AC2993 (synthetic exendin-4) is a peptide that has been shown to stimulate insulin secretion when blood glucose concentrations are high, but not when blood glucose levels are low.
The Product means a pharmaceutical product that contains or incorporates Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration (including, without limitation, all delivery devices or other peripherals and consumables).
This collaboration agreement is for development and sale of a potential new treatment for type 2 diabetes.